Apolizumab

Apolizumab is a humanized monoclonal antibody intended for use in hematologic cancers.
Development was abandoned in 2005 because of toxic effects and lack of efficacy in human patients. The observed dose limiting toxic effects were aseptic meningitis and hemolytic uremia. There are no current clinical trials into its use.